A detailed history of Brevan Howard Capital Management LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 14,918 shares of NTLA stock, worth $208,404. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,918
Holding current value
$208,404
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $294,182 - $408,156
14,918 New
14,918 $306,000
Q2 2021

Aug 13, 2021

SELL
$60.88 - $161.91 $2.24 Million - $5.96 Million
-36,788 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$46.59 - $83.68 $988,732 - $1.78 Million
-21,222 Reduced 36.58%
36,788 $2.95 Million
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $1.09 Million - $3.69 Million
58,010 New
58,010 $3.16 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.06B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.